Found: 83
Select item for more details and to access through your institution.
Proximal versus distal diuretics in congestive heart failure.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 9, p. 1392, doi. 10.1093/ndt/gfae058
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2531, doi. 10.1111/dom.15575
- By:
- Publication type:
- Article
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
- Published in:
- Diabetologia, 2024, v. 67, n. 1, p. 3, doi. 10.1007/s00125-023-06015-1
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3410, doi. 10.1111/dom.15203
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2218, doi. 10.1111/dom.15099
- By:
- Publication type:
- Article
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764
- By:
- Publication type:
- Article
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1646, doi. 10.1111/dom.15019
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.
- Published in:
- Sleep & Breathing, 2023, v. 27, n. 1, p. 77, doi. 10.1007/s11325-022-02606-1
- By:
- Publication type:
- Article
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care.
- Published in:
- Canadian Journal of Kidney Health & Disease, 2023, p. 1, doi. 10.1177/20543581221150556
- By:
- Publication type:
- Article
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care.
- Published in:
- Canadian Journal of Kidney Health & Disease, 2023, v. 10, p. 1, doi. 10.1177/20543581221150556
- By:
- Publication type:
- Article
SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence.
- Published in:
- Clinical Kidney Journal, 2023, v. 16, n. 1, p. 52, doi. 10.1093/ckj/sfac189
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1578, doi. 10.1111/dom.14729
- By:
- Publication type:
- Article
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
- By:
- Publication type:
- Article
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
- Published in:
- Diabetologia, 2022, v. 65, n. 7, p. 1085, doi. 10.1007/s00125-022-05694-6
- By:
- Publication type:
- Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
- By:
- Publication type:
- Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
- Published in:
- International Urology & Nephrology, 2022, v. 54, n. 4, p. 827, doi. 10.1007/s11255-021-02943-2
- By:
- Publication type:
- Article
SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series.
- Published in:
- Canadian Journal of Kidney Health & Disease, 2021, p. 1, doi. 10.1177/20543581211065528
- By:
- Publication type:
- Article
FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes.
- Published in:
- American Journal of Managed Care, 2021, v. 27, p. S375, doi. 10.37765/ajmc.2021.88808
- By:
- Publication type:
- Article
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2632, doi. 10.1111/dom.14513
- By:
- Publication type:
- Article
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 11, p. 2466, doi. 10.1111/dom.14489
- By:
- Publication type:
- Article
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.
- Published in:
- Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665
- By:
- Publication type:
- Article
Discoveries from the study of longstanding type 1 diabetes.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1189, doi. 10.1007/s00125-021-05403-9
- By:
- Publication type:
- Article
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.
- Published in:
- Nephrology, 2021, v. 26, n. 5, p. 377, doi. 10.1111/nep.13839
- By:
- Publication type:
- Article
Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 4, p. 517, doi. 10.1007/s40262-020-00956-1
- By:
- Publication type:
- Article
Cardiorenal Protection in Diabetic Kidney Disease.
- Published in:
- Endocrinology & Metabolism, 2021, v. 36, n. 2, p. 256, doi. 10.3803/EnM.2021.987
- By:
- Publication type:
- Article
SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series.
- Published in:
- Canadian Journal of Kidney Health & Disease, 2021, p. 1, doi. 10.1177/20543581211065528
- By:
- Publication type:
- Article
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 10, p. 1700, doi. 10.1093/ndt/gfaa234
- By:
- Publication type:
- Article
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
- Published in:
- Diabetologia, 2020, v. 63, n. 6, p. 1128, doi. 10.1007/s00125-020-05133-4
- By:
- Publication type:
- Article
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 5, p. 895, doi. 10.1093/ndt/gfz294
- By:
- Publication type:
- Article
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications.
- Published in:
- Endocrine Reviews, 2020, v. 41, n. 2, p. 202, doi. 10.1210/endrev/bnz010
- By:
- Publication type:
- Article
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2368, doi. 10.1111/dom.13831
- By:
- Publication type:
- Article
Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?
- Published in:
- 2019
- By:
- Publication type:
- journal article
Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1388, doi. 10.1111/dom.13665
- By:
- Publication type:
- Article
Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus.
- Published in:
- Diabetologia, 2019, v. 62, n. 6, p. 1090, doi. 10.1007/s00125-019-4871-8
- By:
- Publication type:
- Article
Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 24, doi. 10.1111/dom.13692
- By:
- Publication type:
- Article
The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 575, doi. 10.1111/dom.13556
- By:
- Publication type:
- Article
Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Serum Uromodulin Predicts Less Coronary Artery Calcification and Diabetic Kidney Disease Over 12 Years in Adults With Type 1 Diabetes: The CACTI Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes.
- Published in:
- Diabetes Care, 2018, v. 41, n. 12, p. 2570, doi. 10.2337/dc18-1236
- By:
- Publication type:
- Article
Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
- Published in:
- Diabetologia, 2018, v. 61, n. 10, p. 2098, doi. 10.1007/s00125-018-4669-0
- By:
- Publication type:
- Article
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- letter